$8.17 +0.27 (%) Pozen Inc - NASDAQ

Dec. 19, 2014 | 04:00 PM

Partner Headlines

  1. Mid-Day Market Update: Auspex Pharmaceuticals Jumps Following Positive SD-809 Trial Results; Cliffs Natural Resources Shares Slip

    Benzinga | Dec. 17, 2014 | 13:22PM EST
  2. Mid-Morning Market Update: Markets Open Higher; FedEx Profit Misses Estimates

    Benzinga | Dec. 17, 2014 | 11:18AM EST
  3. Morning Market Losers

    Benzinga | Dec. 17, 2014 | 10:00AM EST
  4. Benzinga's Top #PreMarket Losers

    Benzinga | Dec. 17, 2014 | 08:16AM EST
  5. Mid-Day Market Update: ON Semiconductor Surges On $1 Billion Buyback Plan; POZEN Shares Slip

    Benzinga | Dec. 1, 2014 | 13:43PM EST
  6. Mid-Morning Market Update: Markets Open Lower; Weatherford To Sell Engineered Chemistry, Drilling Fluid Operations to Berkshire's Lubrizol

    Benzinga | Dec. 1, 2014 | 10:23AM EST
  7. Morning Market Losers

    Benzinga | Dec. 1, 2014 | 09:53AM EST
  8. US Stock Futures Rise Ahead Of Earnings, Economic Data

    Benzinga | Oct. 23, 2014 | 07:41AM EST
  9. POZEN Announces Receipt Of Three Patents From The United States Patent And Trademark Office

    Benzinga | Oct. 23, 2014 | 07:30AM EST
  10. UPDATE: Ascendiant Capital Markets Upgrades Pozen Following Q2 Results

    Benzinga | Aug. 8, 2014 | 08:16AM EST
  11. Markets Little Changed Ahead Of The Federal Reserve's Policy Decision

    Benzinga | Jul. 28, 2014 | 16:36PM EST
  12. Fed Says Districts Were Optimistic On Economic Outlook; Yahoo! Falls On Downbeat Results

    Benzinga | Jul. 16, 2014 | 15:57PM EST
  13. Yahoo Falls On Downbeat Results; Time Warner Shares Spike Higher

    Benzinga | Jul. 16, 2014 | 13:36PM EST
  14. Morning Market Losers

    Benzinga | Jul. 16, 2014 | 09:54AM EST
  15. Aura Of Light Shines On Pernix Shares Following Treximet Acquisition

    Benzinga | May. 14, 2014 | 12:36PM EST
  16. POZEN Receives CRL From FDA

    Benzinga | Apr. 28, 2014 | 16:45PM EST
  17. Morning Market Losers

    Benzinga | Apr. 28, 2014 | 09:51AM EST
  18. Benzinga's Top #PreMarket Losers

    Benzinga | Apr. 28, 2014 | 08:09AM EST
  19. Pozen Submits Final Study Report for PA8140/PA32540 Phase 1 Study on Schedule

    Benzinga | Apr. 2, 2014 | 07:32AM EST
  20. Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest EPS Estimates

    Benzinga | Mar. 17, 2014 | 04:42AM EST
  21. Will Horizon Pharma Spike Again On Quarterly Report?

    IBD | Mar. 12, 2014 | 08:02AM EST
  22. Morning Market Losers

    Benzinga | Dec. 31, 2013 | 10:21AM EST
  23. Benzinga's Top #PreMarket Losers

    Benzinga | Dec. 31, 2013 | 08:15AM EST
  24. Benzinga's Top Downgrades

    Benzinga | Dec. 30, 2013 | 09:38AM EST
  25. POZEN New PA8140/PA32540 PDUFA Date is April 25, 2014

    Benzinga | Dec. 23, 2013 | 07:05AM EST
  26. POZEN Announces December 31, 2013 as Ex-Dividend Date for Previously Announced Special Cash Distribution

    Benzinga | Dec. 5, 2013 | 16:24PM EST
  27. Benzinga's Top #PreMarket Gainers

    Benzinga | Nov. 22, 2013 | 08:21AM EST
  28. POZEN Announces Special Cash Distribution of $1.75/Share

    Benzinga | Nov. 21, 2013 | 16:07PM EST
  29. Horizon to Acquire US Rights for VIMOVO from Pozen

    Benzinga | Nov. 19, 2013 | 06:18AM EST
  30. Benzinga's Top Pre-Market Gainers

    Benzinga | Sep. 5, 2013 | 08:10AM EST
  31. Stocks To Watch For September 5, 2013

    Benzinga | Sep. 5, 2013 | 04:20AM EST
  32. SANOFI

    IBD | Sep. 4, 2013 | 18:37PM EST
  33. Sanofi, Pozen Announce Exclusive License Deal for Commercialization of PA8140/PA32540 Tablets in US

    Benzinga | Sep. 4, 2013 | 16:05PM EST
  34. Pozen Inc. Reports Operating Results (10-Q)

    GuruFocus | Nov. 9, 2012 | 07:04AM EST
  35. UPDATE: Ascendiant Capital Markets Initiates POZEN at Buy; Future Royalties Attractive

    Benzinga | Oct. 9, 2012 | 06:25AM EST
  36. POZEN Announces PA32540 Provides Superior Antiplatlet Effects over a Standard of Care Regimen in a Phase 1 Study ("Co-Rx")

    Benzinga | Aug. 29, 2012 | 01:32AM EST
  37. POZEN Provides Positive Update on Its PA Program and Results of Its Type A Meeting with the FDA

    Benzinga | Aug. 23, 2012 | 10:15AM EST
  38. POZEN Receives Patent on PA Products for Treatment of Cardiovascular Disease and Osteoarthritis

    Benzinga | Jun. 26, 2012 | 01:30AM EST
  39. Celgene, Bed Bath & Beyond Among Stocks Gapping Down Thursday

    FoxBusiness | Jun. 21, 2012 | 04:31AM EST
  40. Morning Market Losers

    Benzinga | Jun. 21, 2012 | 03:49AM EST
  41. POZEN Says FDA Does Not Agree That BioEquivalence Was Demonstrated

    Benzinga | Jun. 20, 2012 | 10:02AM EST
  42. POZEN Announces Licensing Deal with Desitin Arzneimittel GMBH for MT 400 Migraine Treatment in 29 European Countries

    Benzinga | May. 8, 2012 | 01:37AM EST
Trading Center